Cynata Therapeutics Limited (ASX:CYP)
0.3600
-0.0150 (-4.00%)
Feb 19, 2026, 4:10 PM AEST
Cynata Therapeutics Revenue
In the fiscal year ending June 30, 2025, Cynata Therapeutics had annual revenue of 1.89M AUD, down -18.59%. Cynata Therapeutics had revenue of -84.99K in the half year ending June 30, 2025.
Revenue
1.89M
Revenue Growth
-18.59%
P/S Ratio
48.09
Revenue / Employee
942.57K
Employees
2
Market Cap
90.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.89M | -430.50K | -18.59% |
| Jun 30, 2024 | 2.32M | 661.33K | 39.98% |
| Jun 30, 2023 | 1.65M | -6.12M | -78.71% |
| Jun 30, 2022 | 7.77M | 6.22M | 402.60% |
| Jun 30, 2021 | 1.55M | -5.47M | -77.95% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Botanix Pharmaceuticals | 5.79M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Neurizon Therapeutics | 1.54M |
Cynata Therapeutics News
- 13 days ago - Cynata Therapeutics Limited (CYYNF) Presents at Euroz Hartleys Healthcare Forum 2026 - Slideshow - Seeking Alpha
- 14 days ago - Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease - Slideshow - Seeking Alpha
- 14 days ago - Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript - Seeking Alpha
- 3 months ago - Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript - Seeking Alpha
- 7 months ago - Cynata Therapeutics Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 7 months ago - Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Cynata Therapeutics Limited (CYYNF) Investor Webinar Call Transcript - Seeking Alpha
- 1 year ago - Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript - Seeking Alpha